FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• FTY720 is an immunomodulatory drug used for multiple sclerosis treatment.
• In vivo, FTY720 is converted to FTY720-P by sphingosine kinase 2.
• The incomplete conversion suggests a balance between kinase and phosphatase activities.

Purpose of the Study:

• To identify which lipid phosphatases dephosphorylate FTY720-P.
• To investigate the role of LPPs and SPPs in FTY720-P metabolism.

Main Methods:

• Overexpression of lipid phosphatases (LPP1-3, SPP1-2) in HEK293 cells.
• In vitro enzymatic assays using cell lysates.
• Experiments on intact cells to assess ecto-phosphatase activity.

Main Results:

• Lipid phosphate phosphatase-3 (LPP3) and S1P phosphatase-1 (SPP1) dephosphorylated FTY720-P in vitro.
• LPP3 demonstrated ecto-phosphatase activity on intact cells.
• LPP3 is identified as the major phosphatase regulating FTY720-P levels in vivo.

Conclusions:

• LPP3 is the primary phosphatase responsible for the dephosphorylation of FTY720-P.
• The activity of LPP3 contributes to the in vivo equilibrium between FTY720 and FTY720-P.
• Understanding this enzymatic balance is crucial for FTY720's therapeutic efficacy in multiple sclerosis.